“…In patients with acute myeloblastic leukemia (AML), the response rate to glucocorticoids is much lower and then only at relatively high doses of drug (27,28,40,68). One might therefore hope that if an SBP were detectable in AML, binding studies on untreated patients might be able to identify steroid-responsive patients and even provide some guidelines for doses needed to saturate the SBP.…”